Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3zeta)

Item number Size Datasheet Manual SDS Delivery time Quantity Price
BPS-79853 2 vials - -

3 - 15 business days*

12,997.00€
 
Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing... more
Product information "Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3zeta)"
Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS-79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells. Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3zeta signaling domain.
Keywords: CD19, B-lymphocyte antigen CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte surface antigen B4
Supplier: BPS Bioscience
Supplier-Nr: 79853

Properties

Application: CAR design validation, Mechanism of Action (MOA) prediction
Species reactivity: human

Handling & Safety

Storage: Liquid nitrogen (store in liquid nitrogen)
Shipping: -80°C (International: °C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3zeta)"
Write a review
or to review a product.
Viewed